These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

614 related items for PubMed ID: 11486395

  • 1. Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients.
    Aurlien E, Holte H, Kvaløy S, Jakobsen E, Rusten LS, Kvalheim G.
    Eur J Haematol Suppl; 2001 Jul; 64():14-20. PubMed ID: 11486395
    [Abstract] [Full Text] [Related]

  • 2. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Aurlien E, Holte H, Pharo A, Kvaløy S, Jakobsen E, Smeland EB, Kvalheim G.
    Bone Marrow Transplant; 1998 May; 21(9):873-8. PubMed ID: 9613778
    [Abstract] [Full Text] [Related]

  • 3. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
    Engelhardt M, Winkler J, Waller C, Lange W, Mertelsmann R, Henschler R.
    Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898
    [Abstract] [Full Text] [Related]

  • 4. Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.
    Mayer J, Vásová I, Korístek Z, Navrátil M, Klabusay M, Doubek M, Vorlícek J, Cernilová I, Vodvárka P, Petráková K.
    Eur J Haematol Suppl; 2001 Jul; 64():21-7. PubMed ID: 11486396
    [Abstract] [Full Text] [Related]

  • 5. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma.
    Moskowitz CH, Glassman JR, Wuest D, Maslak P, Reich L, Gucciardo A, Coady-Lyons N, Zelenetz AD, Nimer SD.
    Clin Cancer Res; 1998 Feb; 4(2):311-6. PubMed ID: 9516916
    [Abstract] [Full Text] [Related]

  • 6. Mobilizing potential of ifosfamide/vinorelbine-based chemotherapy in pretreated malignant lymphoma.
    Magagnoli M, Sarina B, Balzarotti M, Castagna L, Timofeeva I, Nozza A, Bertuzzi A, Siracusano L, Sinnone M, Santoro A.
    Bone Marrow Transplant; 2001 Nov; 28(10):923-7. PubMed ID: 11753545
    [Abstract] [Full Text] [Related]

  • 7. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF.
    Lee JL, Kim S, Kim SW, Kim EK, Kim SB, Kang YK, Lee J, Kim MW, Park CJ, Chi HS, Huh J, Kim SH, Suh C.
    Bone Marrow Transplant; 2005 Mar; 35(5):449-54. PubMed ID: 15654353
    [Abstract] [Full Text] [Related]

  • 8. Mobilisation of peripheral blood stem cells with IVE and G-CSF improves CD34+ cell yields and engraftment in patients with non-Hodgkin's lymphomas and Hodgkin's disease.
    McQuaker I, Haynes A, Stainer C, Byrne J, Russell N.
    Bone Marrow Transplant; 1999 Oct; 24(7):715-22. PubMed ID: 10516673
    [Abstract] [Full Text] [Related]

  • 9. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
    Todisco E, Castagna L, Sarina B, Mazza R, Magagnoli M, Balzarotti M, Nozza A, Siracusano L, Timofeeva I, Anastasia A, Demarco M, Santoro A.
    Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
    [Abstract] [Full Text] [Related]

  • 10. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
    Weaver CH, Schulman KA, Buckner CD.
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
    [Abstract] [Full Text] [Related]

  • 11. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
    Zinzani PL, Tani M, Molinari AL, Stefoni V, Zuffa E, Alinari L, Gabriele A, Bonifazi F, Salvucci M, Tura S, Baccarani M.
    Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357
    [Abstract] [Full Text] [Related]

  • 12. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
    Benedetti G, Patoia L, Giglietti A, Alessio M, Pelicci P, Grignani F.
    Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
    [Abstract] [Full Text] [Related]

  • 13. Ifosfamide and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.
    Mayer J, Korístek Z, Vásová I, Vorlícek J, Vodvárka P.
    Bone Marrow Transplant; 1999 Mar; 23(5):413-9. PubMed ID: 10100553
    [Abstract] [Full Text] [Related]

  • 14. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 15. Mobilization kinetics of peripheral blood progenitor cells after IAPVP-16 salvage chemotherapy plus G-CSF in lymphoproliferative disorders.
    Altés A, López R, Martino R, Martinez C, Cabezudo E, Muñoz L, Santamaría A, Perea G, Briones J, Salar A, Sureda A, Brunet S, Madoz P, Sierra J.
    Bone Marrow Transplant; 2000 Jul; 26(2):127-32. PubMed ID: 10918421
    [Abstract] [Full Text] [Related]

  • 16. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Stamatoullas A, Fruchart C, Bastit D, Boulet D, Moncondult M, Piguet H, Tilly H.
    Cancer; 1996 Jun 01; 77(11):2302-7. PubMed ID: 8635099
    [Abstract] [Full Text] [Related]

  • 17. High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease.
    Weaver CH, Schwartzberg L, Li W, Hazelton B, West W.
    Bone Marrow Transplant; 1996 May 01; 17(5):715-21. PubMed ID: 8733687
    [Abstract] [Full Text] [Related]

  • 18. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
    Hohaus S, Martin H, Wassmann B, Egerer G, Haus U, Färber L, Burger KJ, Goldschmidt H, Hoelzer D, Haas R.
    Bone Marrow Transplant; 1998 Oct 01; 22(7):625-30. PubMed ID: 9818688
    [Abstract] [Full Text] [Related]

  • 19. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
    Haas R, Moos M, Möhle R, Döhner H, Witt B, Goldschmidt H, Murea S, Flentje M, Wannenmacher M, Hunstein W.
    Bone Marrow Transplant; 1996 Feb 01; 17(2):149-55. PubMed ID: 8640159
    [Abstract] [Full Text] [Related]

  • 20. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF.
    Callera F, Cavenaghi L, de Melo CM.
    Transfus Apher Sci; 2009 Apr 01; 40(2):91-5. PubMed ID: 19233728
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.